Latest purchase details: Is Avonib available in China?

Ivosidenib (Ivosidenib) is the first of its kind isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, causing abnormal cell growth and proliferation. Ivonib inhibits mutatedIDH1, thereby preventing the enzymatic activity and further differentiation of cancer cells.

Avosidenib received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2018 for the treatment of relapsed and refractory acute myeloid leukemia in adults. Ivonib is also currently approved for the treatment of newly diagnosed acute myeloid leukemia in older adults, in combination with azacitidine or as a single agent, as well as for the treatment of adults with locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes. The drug was only effective in patients susceptible to IDH1 mutations, indicating elevated levels of the oncometabolite D-2-hydroxyglutarate (D-2HG) in cancer cells. Ivonib inhibits mutant and wild-type IDH1, but not IDH2.

The original drug Ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan. Patients need to purchase this drug in hospitals and other places with the prescription information issued by their doctors. The price of each box of the American original version sold overseas is as high as more than 200,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.